Meeting
2012 ASCO Annual Meeting
Phase II trial of dose-dense temozolomide as initial treatment for progressive low-grade oligodendroglial tumors: A multicentric study of the Italian Association of Neuro-Oncology (AINO).
Authors
Roberta Ruda
Division of Neuro-Oncology, University Hospital San Giovanni Battista, Turin, Italy
Roberta Ruda , Luca Bertero , Elisa Trevisan , Andrea Pace , Carmine Maria Carapella , Cristina Dealis , Manuela Caroli , Marina Faedi , Chiara Bomprezzi , Riccardo Soffietti
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Citation
J Clin Oncol 30, 2012 (suppl; abstr 2037)
DOI
10.1200/jco.2012.30.15_suppl.2037
Abstract #
2037
Poster Bd #
25
Abstract Disclosures
Similar Posters
Poster
2011 ASCO Annual Meeting
TEMOBIC: A ANOCEF phase II study of BCNU and temozolomide (TMZ) combination prior to radiotherapy (RT) in anaplasic oligodendroglial gliomas (AOG).
First Author: O. L. Chinot
Poster
2022 ASCO Annual Meeting
Phase II multicentric Italian trial on repositioning of the antipsychotic drug chlorpromazine and its combination with temozolomide in patients with MGMT unmethylated glioblastoma: The RACTAC trial.
First Author: Giuseppe Lombardi
Poster
2021 ASCO Annual Meeting
A phase II study of anlotinib combined with STUPP regimen in the treatment of patients with newly diagnosed glioblastoma (GBM).
First Author: Peijing Li
Poster
2016 ASCO Annual Meeting
Final report of randomized phase II study of two different outpatient setting regimens, vinorelbine (VNR) with cyclophosphamide (CPA) and temozolomide (TMZ) with etoposide (VP).
First Author: Atsushi Ogawa